Phaseline

Companies › Kind Pharmaceuticals

Kind Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Genitourinary, Hematology, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AND017
HIF-1α stabilizer
HIF1APhase 3Anemia Due to Chronic Kidney Disease; Myelodysplastic Syndromes; β -ThalassemiaDec 2026
AND019–Phase 1Advanced or Metastatic Breast CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05187832AND019Phase 1Advanced or Metastatic Breast CancerOncologyNov 2026
NCT07487727AND017Phase 3Anemia Due to Chronic Kidney DiseaseGenitourinaryDec 2026
NCT06304103AND017Phase 2Myelodysplastic SyndromesHematologyDec 2026
NCT06302491AND017Phase 2β -ThalassemiaHematologyDec 2026
NCT07494409AND017Phase 3Anemia Due to Chronic Kidney DiseaseGenitourinaryApr 2027

Targets

HIF1A (1)

Companies with the same targets

ImmunoGenesis

Companies built like this

Chengdu Suncadia Medicine Apellis Pharmaceuticals Shenzhen Kangzhe Biotechnology Biocity Biopharmaceutics Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.